Three key recommendations to support the development of the value added medicines sector in Europe have been set out by local off-patent industry association Medicines for Europe, in a new white paper that urges the EU to take concrete action to create an environment in which innovation around known molecules can flourish.
Value added medicines typically innovate around known drugs through repositioning medicines for different indications, reformulating them in a way that offers benefits, or combining them in new ways to deliver therapy,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?